An Australian ‘convalescent plasma’ product is to be developed by CSL with the aim of using anti-SARS-CoV-2 immunoglobulin to prevent people with COVID-19 from advancing to more severe disease. The investigational product, to be known as COVID-19 Immunoglobulin, will be developed by CSL Behring Australia at its manufacturing facility in Victoria from the plasma of ...
CSL starts program to produce COVID-19 convalescent plasma product in Australia
By Michael Woodhead
6 May 2020